Albers F, Lou M, Dashti S, Swain C, Rinaldi S, Viallon V
Cancer Causes Control. 2024; 35(6):921-933.
PMID: 38363402
PMC: 11130059.
DOI: 10.1007/s10552-024-01856-6.
Dou H, Li F, Wang Y, Chen X, Yu P, Jia S
Diagn Pathol. 2024; 19(1):5.
PMID: 38178166
PMC: 10765627.
DOI: 10.1186/s13000-023-01433-6.
Wang X, Xue Y
Front Endocrinol (Lausanne). 2023; 14:1193592.
PMID: 37538790
PMC: 10394835.
DOI: 10.3389/fendo.2023.1193592.
Zhao Y, Tao S, Wang Q, Liu Y, Yang W, Zhang S
Transl Cancer Res. 2022; 11(5):1195-1206.
PMID: 35706803
PMC: 9189209.
DOI: 10.21037/tcr-22-667.
Diana A, Carlino F, Buono G, Antoniol G, Famiglietti V, De Angelis C
Front Oncol. 2022; 12:813462.
PMID: 35419293
PMC: 8996175.
DOI: 10.3389/fonc.2022.813462.
Lost but Not Least-Novel Insights into Progesterone Receptor Loss in Estrogen Receptor-Positive Breast Cancer.
Kunc M, Popeda M, Biernat W, Senkus E
Cancers (Basel). 2021; 13(19).
PMID: 34638241
PMC: 8507533.
DOI: 10.3390/cancers13194755.
Significant Diagnostic and Prognostic Value of FLAD1 and Related MicroRNAs in Breast Cancer after a Pan-Cancer Analysis.
Mei M, Song W, Wang Y, Zhang M
Dis Markers. 2021; 2021:6962526.
PMID: 34336008
PMC: 8321750.
DOI: 10.1155/2021/6962526.
The impact of progesterone receptor negativity on oncological outcomes in oestrogen-receptor-positive breast cancer.
Davey M, Ryan E, Folan P, OHalloran N, Boland M, Barry M
BJS Open. 2021; 5(3).
PMID: 34013318
PMC: 8134515.
DOI: 10.1093/bjsopen/zrab040.
Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer.
Li Y, Yang D, Yin X, Zhang X, Huang J, Wu Y
JAMA Netw Open. 2020; 3(1):e1918160.
PMID: 31899528
PMC: 6991239.
DOI: 10.1001/jamanetworkopen.2019.18160.
Single hormone receptor-positive breast cancer patients experienced poor survival outcomes: a systematic review and meta-analysis.
Wu N, Fu F, Chen L, Lin Y, Yang P, Wang C
Clin Transl Oncol. 2019; 22(4):474-485.
PMID: 31222450
DOI: 10.1007/s12094-019-02149-0.
Higher ER load is not associated with better outcome in stage 1-3 breast cancer: a descriptive overview of quantitative HR analysis in operable breast cancer.
Noordhoek I, de Groot A, Cohen D, Liefers G, Portielje J, Kroep J
Breast Cancer Res Treat. 2019; 176(1):27-36.
PMID: 30997625
PMC: 6548750.
DOI: 10.1007/s10549-019-05233-9.
Molecular Insights into the Classification of Luminal Breast Cancers: The Genomic Heterogeneity of Progesterone-Negative Tumors.
Lopez G, Costanza J, Colleoni M, Fontana L, Ferrero S, Miozzo M
Int J Mol Sci. 2019; 20(3).
PMID: 30691046
PMC: 6386970.
DOI: 10.3390/ijms20030510.
Improving accuracy of breast cancer biomarker testing in India.
Shet T
Indian J Med Res. 2018; 146(4):449-458.
PMID: 29434058
PMC: 5819026.
DOI: 10.4103/ijmr.IJMR_896_16.
Correlation Between Anthropometric Measures and Biomarker Changes After Neoadjuvant Therapy With Tamoxifen or Anastrozole in Postmenopausal Women With Breast Cancer.
Cintra K, Mattar A, Joo Y, Melitto A, Gonzales R, Nonogaki S
World J Oncol. 2017; 1(3):111-117.
PMID: 29147190
PMC: 5649934.
DOI: 10.4021/wjon2010.06.224w.
The value of FATS expression in predicting sensitivity to radiotherapy in breast cancer.
Zhang J, Wu N, Zhang T, Sun T, Su Y, Zhao J
Oncotarget. 2017; 8(24):38491-38500.
PMID: 28402275
PMC: 5503548.
DOI: 10.18632/oncotarget.16630.
Immunohistochemical determination of estrogen and progesterone receptors in breast cancer: relationship with clinicopathologic factors in 302 patients in Ivory Coast.
Effi A, Aman N, Koui B, Koffi K, Traore Z, Kouyate M
BMC Cancer. 2017; 17(1):115.
PMID: 28173783
PMC: 5297122.
DOI: 10.1186/s12885-017-3105-z.
The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone.
Campbell E, Tesson M, Doogan F, Mohammed Z, Mallon E, Edwards J
Br J Cancer. 2016; 115(8):967-973.
PMID: 27657341
PMC: 5061898.
DOI: 10.1038/bjc.2016.206.
Evaluation of three commercial progesterone receptor assays in a single tamoxifen-treated breast cancer cohort.
Kornaga E, Klimowicz A, Guggisberg N, Ogilvie T, Morris D, Webster M
Mod Pathol. 2016; 29(12):1492-1500.
PMID: 27562489
DOI: 10.1038/modpathol.2016.151.
Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes.
Dai X, Xiang L, Li T, Bai Z
J Cancer. 2016; 7(10):1281-94.
PMID: 27390604
PMC: 4934037.
DOI: 10.7150/jca.13141.
Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer.
Singhal H, Greene M, Tarulli G, Zarnke A, Bourgo R, Laine M
Sci Adv. 2016; 2(6):e1501924.
PMID: 27386569
PMC: 4928895.
DOI: 10.1126/sciadv.1501924.
